Inhibition of endothelin production by adrenomedullin in vascular smooth muscle cells. 1995

M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
First Department of Internal Medicine, Osaka City University Medical School, Japan.

Adrenomedullin recently has been found to potently stimulate cAMP formation in cultured rat vascular smooth muscle cells (VSMCs). In the present study, we examined the effect of adrenomedullin on the production of a vasoconstrictive and growth-promoting peptide, endothelin-1, after stimulation with a clotting enzyme, thrombin, and a potent mitogen, platelet-derived growth factor (PDGF), in cultured rat VSMCs. Thrombin and PDGF stimulated endothelin-1 production in a dose-dependent manner. Rat adrenomedullin significantly inhibited thrombin- and PDGF-stimulated endothelin-1 production in a dose-dependent manner between 10(-7) and 10(-9) mol/L. Inhibition by rat adrenomedullin of thrombin- and PDGF-stimulated endothelin-1 production was paralleled by an increase in the cellular level of cAMP. Human adrenomedullin also inhibited thrombin- and PDGF-stimulated endothelin-1 production and increased cAMP levels. The addition of 8-bromo-cAMP, a cAMP analogue, reduced thrombin- and PDGF-induced endothelin-1 production. Furthermore, forskolin, a potent activator of adenylate cyclase, reduced thrombin- and PDGF-induced endothelin-1 production. In contrast, basal production of endothelin-1 was not altered by rat or human adrenomedullin. These results indicate that adrenomedullin inhibits not basal but thrombin- and PDGF-induced ET-1 production in cultured VSMCs probably through a cAMP-dependent process. Taken together with the finding that adrenomedullin is synthesized in and secreted from vascular endothelial cells, adrenomedullin may modulate vascular tone as a paracrine regulator partially through the inhibition of VSMC endothelin-1 production in some pathophysiological states.

UI MeSH Term Description Entries
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010982 Platelet-Derived Growth Factor Mitogenic peptide growth hormone carried in the alpha-granules of platelets. It is released when platelets adhere to traumatized tissues. Connective tissue cells near the traumatized region respond by initiating the process of replication. Platelet Derived Growth Factor,Factor, Platelet-Derived Growth,Growth Factor, Platelet-Derived
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D005576 Colforsin Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant COLEUS FORSKOHLII. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. Coleonol,Forskolin,N,N-Dimethyl-beta-alanine-5-(acetyloxy)-3-ethenyldodecahydro-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-1H-naphtho(2,1-b)pyran-6-yl Ester HCl,NKH 477,NKH-477,NKH477
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin
D015124 8-Bromo Cyclic Adenosine Monophosphate A long-acting derivative of cyclic AMP. It is an activator of cyclic AMP-dependent protein kinase, but resistant to degradation by cyclic AMP phosphodiesterase. 8-Bromo-cAMP,8-Br Cyclic AMP,8-Bromo Cyclic AMP,8-Bromo Cyclic Adenosine Monophosphate, Monosodium Salt,8-Bromo Cyclic Adenosine Monophosphate, Sodium Salt,8-Bromoadenosine 3',5'-Cyclic Monophosphate,Br Cycl AMP,8 Br Cyclic AMP,8 Bromo Cyclic AMP,8 Bromo Cyclic Adenosine Monophosphate,8 Bromo Cyclic Adenosine Monophosphate, Monosodium Salt,8 Bromo Cyclic Adenosine Monophosphate, Sodium Salt,8 Bromo cAMP,8 Bromoadenosine 3',5' Cyclic Monophosphate,AMP, Br Cycl,Cyclic AMP, 8-Br,Cyclic AMP, 8-Bromo
D016232 Endothelins 21-Amino-acid peptides produced by vascular endothelial cells and functioning as potent vasoconstrictors. The endothelin family consists of three members, ENDOTHELIN-1; ENDOTHELIN-2; and ENDOTHELIN-3. All three peptides contain 21 amino acids, but vary in amino acid composition. The three peptides produce vasoconstrictor and pressor responses in various parts of the body. However, the quantitative profiles of the pharmacological activities are considerably different among the three isopeptides. Endothelium-Derived Vasoconstrictor Factors,Endothelin,Vasoconstrictor Factors, Endothelium-Derived

Related Publications

M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
January 1991, Journal of cardiovascular pharmacology,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
October 1996, Regulatory peptides,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
August 1994, Biochemical and biophysical research communications,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
January 2001, Journal of cardiovascular pharmacology,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
March 1999, Research communications in molecular pathology and pharmacology,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
August 1992, Journal of cardiovascular pharmacology,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
June 1978, Lancet (London, England),
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
January 1999, Molecular and cellular endocrinology,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
June 2002, Journal of hypertension,
M Kohno, and H Kano, and T Horio, and K Yokokawa, and K Yasunari, and T Takeda
January 1993, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!